Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Harper, Forbes"'
Publikováno v:
ZooKeys, Vol 1185, Iss , Pp 199-239 (2023)
Herein a new species of Paruroctonus Werner, 1934 is described from alkali-sink habitats in the San Joaquin Desert of central California, Paruroctonus tulare sp. nov. It can be differentiated from other Paruroctonus by a combination of morphological
Externí odkaz:
https://doaj.org/article/22f6bde14dd54bb3ab407627e253836a
Publikováno v:
ZooKeys, Vol 1117, Iss , Pp 139-188 (2022)
Herein we describe two new species of Paruroctonus (Werner 1934) from California: Paruroctonus soda sp. nov. from the Soda Lake playa at the center of the Carrizo Plain in San Luis Obispo county and Paruroctonus conclusus sp. nov. from the Koehn Lake
Externí odkaz:
https://doaj.org/article/2c6f888ec0ee42cca803929b144dd68c
Autor:
Ralf Gutzmer, Caroline Robert, Gabriella Liszkay, Grant McArthur, Jacek Mackiewicz, Rodrigo Munhoz, Paolo Ascierto, Judit Olah, Paola Queirolo, Luis De La Cruz Marino, Kalpit Shah, Harper Forbes, Christian Hertig, Yibing Yan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/f0de46026009415e8098531206f1d714
Autor:
Enric Bertran, Grant R. Goodman, Harper Forbes, Weijiang Zhang, M. Mathisen, Lev V. Demidov, Sang Joon Shin, Yuyao Song
Publikováno v:
Clinical Pharmacology in Drug Development. 10:39-45
The effects of itraconazole, a strong CYP3A4 inhibitor, on the steady-state pharmacokinetics of vemurafenib were evaluated in a phase 1, multicenter, open-label, fixed-sequence study. Patients with BRAFV600 mutation-positive metastatic malignancies r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b7b6fd6781c799711ce62e5e2475872
https://doi.org/10.1002/cpdd.822
https://doi.org/10.1002/cpdd.822
Autor:
Jeeyun Lee, Hye Jin Choi, Dae Ho Lee, Christine McIntyre, Weijiang Zhang, Enric Bertran, Todd Riehl, Harper Forbes
Publikováno v:
Clinical Pharmacology in Drug Development. 9:651-658
This phase 1 open-label, multicenter, 3-period, fixed-sequence study evaluated the effect of multiple doses of vemurafenib on the pharmacokinetics of 1 dose of tizanidine, a probe CYP1A2 substrate, in patients with BRAFV600 mutation-positive metastat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ed39d4a0b8b63611a643d7fb0ae9b6e
https://doi.org/10.1002/cpdd.788
https://doi.org/10.1002/cpdd.788
Autor:
Dawn Colburn, Weijiang Zhang, Dieter Roethlisberger, Enric Bertran, B. Simmons, Simone Schadt, Zsuzsanna Papai, Harper Forbes, Thomas Hartung, Christophe Husser
Publikováno v:
Clinical Pharmacology in Drug Development. 9:496-504
Vemurafenib is a BRAF kinase inhibitor indicated for the treatment of patients with BRAFV600 mutation-positive unresectable or metastatic melanoma and Erdheim-Chester disease. This phase 1, open-label, single-arm study was designed to estimate absolu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::850f330bdac750aa724c78210b0c41d8
https://doi.org/10.1002/cpdd.773
https://doi.org/10.1002/cpdd.773
Autor:
Judit Oláh, Grant A. McArthur, Kalpit Shah, Caroline Robert, Karl D. Lewis, Luis De La Cruz Marino, Paola Queirolo, Paolo A. Ascierto, Christian Hertig, Jacek Mackiewicz, Harper Forbes, Gabriella Liszkay, Ralf Gutzmer, Rodrigo Ramella Munhoz, Yibing Yan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background The phase 3 IMspire150 study (NCT02908672) showed that first-line atezolizumab (A) combined with vemurafenib (V) + cobimetinib (C) improved progression-free survival (PFS) vs placebo (P) + V + C in patients with BRAFV600 mutation–positiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcae1e60a93a7bff1fb691e8f7f9c95c
https://doi.org/10.1136/jitc-2020-sitc2020.0307
https://doi.org/10.1136/jitc-2020-sitc2020.0307
Autor:
Weijiang, Zhang, Michael, Mathisen, Grant R, Goodman, Harper, Forbes, Yuyao, Song, Enric, Bertran, Lev, Demidov, Sang Joon, Shin
Publikováno v:
Clinical pharmacology in drug developmentReferences. 10(1)
The effects of itraconazole, a strong CYP3A4 inhibitor, on the steady-state pharmacokinetics of vemurafenib were evaluated in a phase 1, multicenter, open-label, fixed-sequence study. Patients with BRAF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f37b4b7fd4a2067e153582c5f444654d
https://pubmed.ncbi.nlm.nih.gov/32602215
https://pubmed.ncbi.nlm.nih.gov/32602215
Autor:
Weijiang, Zhang, Christine, McIntyre, Todd, Riehl, Harper, Forbes, Enric, Bertran, Hye Jin, Choi, Dae Ho, Lee, Jeeyun, Lee
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(5)
This phase 1 open-label, multicenter, 3-period, fixed-sequence study evaluated the effect of multiple doses of vemurafenib on the pharmacokinetics of 1 dose of tizanidine, a probe CYP1A2 substrate, in patients with BRAF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::19b488c73dc5778e4080ce0cc964bc5f
https://pubmed.ncbi.nlm.nih.gov/32311241
https://pubmed.ncbi.nlm.nih.gov/32311241
Autor:
Melissa Kuhn, Jeeyun Lee, Weijiang Zhang, Christine McIntyre, Dawn Colburn, Lev Demidov, Tae Min Kim, Harper Forbes
Publikováno v:
The Journal of Clinical Pharmacology. 58:1067-1073
The primary objective of this phase 1, open-label, multicenter, 3-period, fixed-sequence study was to evaluate the effect of multiple doses of vemurafenib on the pharmacokinetics of a single dose of digoxin, a probe P-glycoprotein (P-gp) substrate, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb8cf7c5b3ebc3365295c98efa5ca9d6
https://doi.org/10.1002/jcph.1111
https://doi.org/10.1002/jcph.1111